Physician profile
Parul Dev
NPI 1962610634
$3,232.14
in general payments reported to CMS, 2019-2025
23 companies · $677 in 2025
The $677 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $227 · 2021: $183 · 2022: $296 · 2023: $658 · 2024: $693 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.77 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.75 | 2021-2025 | Vraylar, Botox, Ubrelvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $414.16 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $331.23 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $309.87 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $249.46 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $215.08 | 2019-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $186.22 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $165.27 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $142.73 | 2019-2020 | |
| Eisai INC. | $118.88 | 2024 | |
| Neurocrine Biosciences, INC. | $118.82 | 2019-2025 | Ingrezza |
| Corium, LLC | $93.10 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $71.17 | 2019-2024 | |
| Allergan, INC. | $54.21 | 2020 | |
| Avanir Pharmaceuticals, INC. | $47.60 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47.37 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $42.17 | 2022-2025 | Trintellix |
| Tris Pharma INC | $42.09 | 2022-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $27.89 | 2023-2024 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $26.94 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $24.75 | 2023 | Qelbree |
| Neos Therapeutics, Lp | $19.04 | 2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $15.34 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Dev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.